Midatech Pharma PLC (MTP)

Overview

Midatech Pharma plc operates as a pioneering drug delivery technology company with a primary focus on the development and research of pharmaceuticals. Founded in the year 2000 and with its headquarters situated in Cardiff, United Kingdom, the company makes its presence known not only domestically but also across Europe and internationally. Midatech Pharma is dedicated to the advancement of innovative therapies that aim to solve unmet medical needs, and it leverages its proprietary drug delivery technologies to achieve this goal. Through its dedication to research and development, Midatech Pharma aspires to bring revolutionary treatments to patients suffering from serious diseases.

Products and Services

• MTX110: This is a novel direct delivery treatment that is currently in development for treating diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme. By directly delivering the treatment to the site of the disease, MTX110 aims to improve efficacy and reduce side effects associated with traditional systemic administration.
• MTX114: An innovative topical immuno-suppressant designed for the treatment of psoriasis. By applying MTX114 directly to the affected skin, the goal is to suppress the immune response locally, thereby reducing psoriasis symptoms without the systemic side effects of oral immuno-suppressants.
• MTD211: A long-acting formulation of brexpiprazole, focused on the treatment of schizophrenia and as an adjunct therapy for major depressive disorder. The extended-release aspect of MTD211 is designed to ensure steady medication levels in the bloodstream, potentially improving patient compliance and outcomes.
• MTD219: A long-acting tacrolimus formulation aimed at reducing the risk of organ transplant rejection. By maintaining consistent drug levels over an extended period, MTD219 seeks to improve the success rates of organ transplants by effectively managing the immune response.
• Drug Delivery Platforms: Midatech Pharma also offers a suite of proprietary drug delivery technologies including:
  • Q-Sphera: A polymer microsphere technology utilized for sustained release drug delivery. This platform aims to ensure a controlled release of medications, enhancing treatment efficacy and patient adherence.
  • MidaSolve: An oligosaccharide-based nanotechnology designed to solubilize drugs for direct and localized administration into tumors. This technology aims to improve the bioavailability of drugs at the site of the tumor, potentially enhancing therapeutic effects.
  • MidaCore: Leveraging gold nanoparticles for the targeted delivery of chemotherapeutic or immunotherapeutic agents directly to disease sites. MidaCore is engineered to enhance the accuracy of drug delivery, focusing the therapeutic action on the intended targets while minimizing systemic exposure.